This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Dr. Lindenmayer Replies

Jean-Pierre Lindenmayer, MD

Published: January 15, 2008

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: In his letter to the editor, Dr. Murphy opines against theuse of a first-generation antipsychotic as a comparator in ourstudy,1 stating that "the mean dose of haloperidol used (17.11mg) invariably induces secondary negative symptoms."However, there is little evidence that haloperidol systematicallyinduces secondary negative symptoms. In fact, 2recent studies2,3 comparing the effects of olanzapine, a secondgenerationantipsychotic with a very benign extrapyramidalsymptom profile, with haloperidol at doses similar to those usedin our study combined with benztropine found no significantdifferences for positive or negative symptoms in schizophreniabetween the 2 antipsychotics. ‘ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 69

Quick Links: Psychiatry

Sign-up to stay
up-to-date today!


Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...